IQVIA Holdings Inc. ($IQV) Stock Forecast: Up 1.8% Today

What is IQVIA Holdings Inc.?

IQVIA Holdings, Inc. (IQV) is a prominent player in the healthcare sector, known for its robust service offerings and strategic market position. Today, the stock experienced a strong bullish movement, reflecting positive investor sentiment.

Why is IQVIA Holdings Inc. going up?

IQV stock is up 1.8% on Jan 20, 2026 15:35

• IQV's bullish movement can be attributed to its strong financial performance, technical indicators, and analyst confidence, indicating a promising investment opportunity.
• The increased stake by an investment firm and the company's strong Q3 earnings, beating analyst expectations, likely contributed to the positive market movement.
• Additionally, the overall rebound in the healthcare sector, driven by increased clarity on drug pricing and tariffs, may have further boosted IQV's performance as a top pick for investors in 2026.
• The company's current trading above key moving averages and consensus "Moderate Buy" rating with an average target price near $249.19 reinforce the bullish outlook for IQV.

IQV Price Chart

IQV Technical Analysis

IQV News

IQVIA Holdings, Inc. (IQV) Stock Analysis: Strong Buy Signals And A 9.24% Upside Potential

IQVIA Holdings, Inc. (IQV) exhibits strong financial performance, technical indicators, and analyst confidence, suggesting a promising investment opportunity. With a 9.24% potential upside based on analyst target prices and no sell ratings, the company's robust service offerings and strategic market position make it an attractive stock in the healthcare sector. Its current trading above key moving averages reinforces a bullish outlook for investors.

https://www.directorstalkinterviews.com/iqvia-holdings-inc-iqv-stock-analysis-strong-buy-signals-and-a-9-24-upside-potential/4121235484

Thermo Fisher Scientific (TMO) Valuation After Leadership Shakeup And New AI Lab Partnerships

Thermo Fisher Scientific (TMO) is gaining attention due to leadership changes, a manufacturing site closure, and new AI partnerships with NVIDIA and TetraScience, influencing its growth prospects. While a popular narrative suggests a modest undervaluation at US$641.57 based on long-term earnings, Simply Wall St's DCF model estimates the fair value at US$605.48, making the stock appear slightly overvalued. Investors should consider both valuation perspectives and potential risks like softer demand from academic and government customers and China-related pressures.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-tmo/thermo-fisher-scientific/news/thermo-fisher-scientific-tmo-valuation-after-leadership-shak

Drug trials get new oxygen sensor as Profusa enters $47.9B CRO market

Profusa (PFSA) has launched its Lumee tissue oxygen Healthcare Research offering, making research-use-only (RUO) Lumee kits and a service-enabled platform commercially available to contract research organizations (CROs). This initiative targets the global CRO market, valued at $47.9 billion in 2025 with a projected 7% CAGR, to generate near-term service revenue by providing continuous, real-time tissue oxygen measurements for various R&D applications. Sean Givens has been appointed to lead the commercialization efforts for this new venture.

https://www.stocktitan.net/news/PFSA/profusa-launches-lumee-tm-tissue-oxygen-healthcare-research-oc62nqhazlj9.html

Stephens Inc. AR Grows Stake in IQVIA Holdings Inc. $IQV

Stephens Inc. AR significantly increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 36.9% in the third quarter, now holding 27,728 shares valued at $5.27 million. Institutional investors collectively own a substantial 89.62% of the company. IQVIA also reported strong Q3 earnings, beating analyst expectations, and has a consensus "Moderate Buy" rating with an average target price near $249.19.

https://www.marketbeat.com/instant-alerts/filing-stephens-inc-ar-grows-stake-in-iqvia-holdings-inc-iqv-2026-01-16/

Healthcare: Increased Clarity on Drug Pricing and Tariffs Led to a Healthcare Rebound

The Morningstar Healthcare Index rebounded in the fourth quarter of 2025, narrowing its gap with the broader market, largely due to increased clarity on US drug pricing policies and healthcare tariffs. The sector is seen as fairly valued overall, with medical distribution being overvalued while healthcare plans and providers appear undervalued. Top picks for 2026 include GE HealthCare, Elevance Health, and IQVIA, benefiting from defensive profiles, innovation, and strong competitive advantages in growth areas like GLP-1 and renal denervation markets.

https://www.morningstar.com/stocks/healthcare-increased-clarity-drug-pricing-tariffs-led-healthcare-rebound

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 6.3% Today

Binance Coin ($BNB) Crypto Forecast: Down 5.0% Today

Natural Gas ($GAS) Commodity Forecast: Up 29.2% Today

The Sandbox ($SAND) Crypto Forecast: Up 5.1% Today

TRON ($TRX) Crypto Forecast: Down 5.0% Today

Dash ($DASH) Crypto Forecast: Down 5.7% Today

Monero ($XMR) Crypto Forecast: Down 18.9% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.0% Today

FuelCell Energy ($FCEL) Stock Forecast: Up 5.2% Today

Enphase Energy Inc. ($ENPH) Stock Forecast: Down 5.8% Today

IQVIA Holdings Inc. Price History

28.09.2025 - IQV Stock was up 0.8%

• IQVIA Holdings (IQV) reported better-than-expected earnings and revenue for the third quarter, indicating strong financial performance.
• The company's focus on biopharma strength and cost control has likely contributed to the positive results, showcasing its ability to adapt to industry dynamics.
• Investors may be optimistic about IQV's future prospects, considering its ability to outperform expectations in a challenging market environment.
• The bullish movement in IQV's stock price could be a reflection of confidence in the company's strategic direction and growth potential.

24.06.2025 - IQV Stock was up 7.6%

• IQV stock had a strong bullish movement today.
• The positive earnings report for the second quarter, with earnings and revenue beating estimates and showing year-over-year growth, likely fueled the bullish trend.
• Despite the strong performance, the cut in 2025 EBITDA guidance may have tempered some of the initial excitement in the market.
• The overall market uncertainty could have been overshadowed by IQV's impressive financial results, leading to the bullish movement in the stock.

05.00.2026 - IQV Stock was up 1.0%

• The increased stake by North Growth Management Ltd. and positive Q3 earnings results exceeding expectations likely contributed to the bullish movement.
• Despite the reduction in holdings by JARISLOWSKY FRASER Ltd and Generali Asset Management SPA SGR, the overall sentiment from analysts and brokers with raised price targets and ratings supported the stock's upward trajectory.
• The contrast between IQVIA's steady growth and undervalued perception of ICON plc in the clinical research space may have also attracted investors looking for reliable long-term investments.
• Overall, the combination of positive institutional investments, strong financial performance, and optimistic future guidance propelled IQV's bullish movement in the market today.

20.00.2026 - IQV Stock was up 1.8%

• IQV's bullish movement can be attributed to its strong financial performance, technical indicators, and analyst confidence, indicating a promising investment opportunity.
• The increased stake by an investment firm and the company's strong Q3 earnings, beating analyst expectations, likely contributed to the positive market movement.
• Additionally, the overall rebound in the healthcare sector, driven by increased clarity on drug pricing and tariffs, may have further boosted IQV's performance as a top pick for investors in 2026.
• The company's current trading above key moving averages and consensus "Moderate Buy" rating with an average target price near $249.19 reinforce the bullish outlook for IQV.

07.04.2025 - IQV Stock was up 5.5%

• Impressive Q1 earnings and revenues exceeded analysts' projections, particularly in the Research and Development, and Technology and Analytics sectors.
• CEO's mention of the company's adept handling of uncertain market conditions boosted investor confidence and generated positive market sentiment towards IQVIA.
• The increased sales outlook for 2025 and upheld EPS guidance added to the positive momentum, indicating a promising growth path for the company in the upcoming quarters.
• IQVIA's strong financial performance and strategic positioning in significant segments drove the stock to a bullish trajectory, demonstrating investors' confidence in the company's future outlook.

06.00.2026 - IQV Stock was up 5.5%

• Some investors, including Community Trust & Investment Co., have reduced their stakes in IQVIA Holdings Inc., while others like Asset Dedication LLC and J.Safra Asset Management Corp. have increased their holdings, showing mixed sentiments among investors.
• IQVIA stock reached a 52-week high due to strong market performance, recent strategic decisions such as refinancing loans and a collaboration with Amazon Web Services, and positive adjustments in analyst price targets, reflecting investor confidence and growth prospects.
• The temporary suspension of the new 340B Drug Pricing Program rebate model may have had a positive impact on IQVIA by easing financial pressures on hospitals and potentially increasing demand for IQVIA's services in the life sciences sector.
• Despite competition from companies like Charles River Laboratories and ICON plc, IQVIA's strategic positioning and recent positive developments are likely contributing to its bullish market movement today.

08.06.2025 - IQV Stock was up 2.2%

• A 29.88% increase in IQV's short percent of float could indicate a growing bearish sentiment among investors.
• Despite the rise in short interest, the stock experienced a bullish movement, suggesting potential positive developments driving investor optimism.
• Investor positivity may be linked to recent company announcements, strategic partnerships, or earnings reports, resulting in the upward movement of IQV's stock price.
• Monitoring short interest data and market trends is crucial for traders to make informed decisions about IQV's future performance.

06.04.2025 - IQV Stock was down 4.4%

• The bearish movement in IQV's stock today could be due to investors' concerns about the upcoming Q1 earnings.
• Despite anticipated growth in the R&DS and TAS segments, investors may be cautious about the company's overall performance for the quarter.
• Insights from analysts on key performance measures might have raised doubts or uncertainty among investors, leading to the bearish market movement.
• Market participants may be waiting for the earnings release to gain a clearer picture of IQVIA's financial health and future outlook, causing the stock to decline in the short term.

10.03.2025 - IQV Stock was down 5.9%

• Despite a recent surge in share price, IQVIA (IQV) experienced a strong bearish movement today.
• The bullish movement in the last session may have been short-lived, as the latest trend in earnings estimate revisions does not support further price increase in the near term.
• The market may have reacted negatively to this disconnect between the recent price surge and the lack of support from earnings estimates, leading to the bearish movement in IQV's stock today.

22.06.2025 - IQV Stock was up 15.7%

• IQV is experiencing a strong bullish movement today, likely driven by positive market sentiment and anticipation surrounding its upcoming Q2 earnings.
• Analysts are optimistic about IQV's performance for the quarter, with expectations of both earnings and revenues to rise on the back of strong demand across its segments.
• Investors may be reacting positively to the potential growth in earnings, despite some concerns raised about the company not meeting all the key expectations for a likely earnings beat.
• Overall, the bullish movement in IQV's stock today could be attributed to the market's optimism and anticipation of a positive earnings, outweighing any potential concerns about meeting all expectations.

22.06.2025 - IQV Stock was up 17.5%

• IQVIA (IQV) experienced a strong bullish movement today following its Q2 earnings report.
• The company surpassed earnings and revenue estimates for the quarter, showcasing a 6.4% increase in earnings and a 5.5% rise in revenue year-over-year.
• Despite cutting its 2025 EBITDA guidance, investors were optimistic about IQVIA's performance, driven by strong demand across its segments.
• The positive earnings report and optimistic outlook for the stock propelled IQV's bullish movement as investors showed confidence in the company's ability to deliver results in a competitive market.

04.11.2025 - IQV Stock was down 5.2%

• Today, the market witnessed a bearish movement despite IQV's recent stock price increase and optimistic Q3 financial results.
• The decline could be attributed to some investors seizing the opportunity to take profits after the stock's substantial growth in recent months.
• Analysts' positive outlook on IQVIA Holdings, evident through the "Strong Buy" consensus rating and raised price targets, implies that the current bearish trend may be a temporary correction rather than a prolonged shift.
• Amidst uncertainties in the broader market, investors appear to be reassessing their positions in IQVIA Holdings, resulting in a bearish movement despite favorable company-specific developments.